On January 23, 2020, Carl Goldfischer, M.D. and Evan Stein, M.D., Ph.D. resigned as directors of CymaBay Therapeutics, Inc., effective immediately. In addition, on January 24, 2020, Robert Booth, Ph. D. and Robert Weiland resigned as directors of CymaBay, effective immediately. In conjunction with these resignations and in order to reduce the costs of operating a larger Board of Directors, on January 27, 2020 CymaBay reduced the size of its Board of Directors to five members.